Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 8 peer-reviewed journal articles Updated
Oncology · Extranodal nasal NK/T-cell lymphoma

Staging and Understanding Your PINK-E Risk Score

At a Glance

The PINK-E score is the gold standard for predicting how Extranodal nasal NK/T-cell lymphoma (ENKTL) will behave. It uses five factors—age, stage, distant lymph nodes, tumor location, and EBV DNA levels—to determine risk groups and guide treatment.

Staging is the process of determining how far a cancer has spread. While many cancers use the standard Ann Arbor Staging System, doctors have found that this system alone isn’t enough for Extranodal nasal NK/T-cell lymphoma (ENKTL) [1][2]. Because this lymphoma is so unique, experts developed specialized “Risk Scores” called PINK and PINK-E to better understand each patient’s situation and tailor their care [3].

The Standard: Ann Arbor Staging

The Ann Arbor system is a general way of describing where lymphoma is located [4]. In ENKTL, it is often less precise than other tools because the disease can be very aggressive even if it is only in one small area [2][5].

  • Stage I/II: The lymphoma is limited to one or two areas on the same side of the diaphragm (the breathing muscle between the chest and abdomen).
  • Stage III/IV: The lymphoma has spread to both sides of the diaphragm or to distant organs [4].

The Gold Standard: The PINK and PINK-E Scores

Because Ann Arbor staging has limits, researchers created the Prognostic Index for Natural Killer Lymphoma (PINK). This score looks at your overall health and specific cancer traits to predict how the disease might behave [3].

There are five variables used to calculate these scores:

  1. Age: Being over 60 years old [3].
  2. Stage: Being Stage III or IV [3].
  3. Distant Lymph Nodes: Finding cancer in lymph nodes far away from the primary tumor site [3].
  4. Non-Nasal Type: The lymphoma started in a place other than the nose (like the skin or GI tract) [3].
  5. EBV DNA (The “E” in PINK-E): Having a detectable level of the Epstein-Barr virus in your blood [3][6].

Understanding Your Risk Group

The PINK-E score is widely considered the most accurate because it includes the “E” for EBV DNA [3]. Depending on how many of those five factors apply to you, you are placed into a risk group.

PINK-E Risk Group Number of Factors 3-Year Overall Survival Rate
Low Risk 0 or 1 Factor 81% [3]
Intermediate Risk 2 Factors 55% [3]
High Risk 3 or more Factors 28% [3]

Why This Matters for You

These scores are not “destiny,” but they are powerful tools for empowerment. Your doctor uses these groups to decide how aggressive your treatment needs to be [3]. For example, someone in a “Low Risk” group might receive different chemotherapy or radiation than someone in a “High Risk” group [3]. Knowing your score helps you understand the “why” behind your doctor’s recommendations and ensures you are receiving the most appropriate care for your specific profile.

To get an accurate score, your team must perform a PET/CT scan to look for distant lymph nodes and a specialized plasma EBV-DNA test [7][8]. If you don’t see these results in your records, it is a great time to ask your doctor for them.

Common questions in this guide

What is the PINK-E score for ENKTL?
The PINK-E score is a specialized tool used to predict how Extranodal nasal NK/T-cell lymphoma will behave. It looks at your age, stage, lymph node involvement, tumor location, and the levels of Epstein-Barr virus (EBV) in your blood.
How is Extranodal nasal NK/T-cell lymphoma staged?
ENKTL is initially staged using the standard Ann Arbor Staging System, which identifies where the lymphoma is located in the body. However, because ENKTL is unique, doctors rely heavily on the specialized PINK or PINK-E risk scores for a more accurate assessment.
What does the 'E' in the PINK-E score stand for?
The 'E' stands for Epstein-Barr virus (EBV) DNA. A specialized blood test checks for detectable levels of this virus, which is an important factor doctors use to calculate your risk group and accurately plan your treatment.
How does my PINK-E risk score affect my treatment?
Your risk score helps your oncology team decide how aggressive your treatment needs to be. For example, a patient in a 'Low Risk' group may receive a different type or intensity of chemotherapy or radiation than someone in a 'High Risk' group.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my PINK score and my PINK-E score based on my recent tests?
  2. 2.Is my lymphoma classified as 'nasal type' or 'non-nasal type,' and how does that change the approach?
  3. 3.Were my PET/CT results positive for 'distant lymph nodes'?
  4. 4.Was my plasma EBV-DNA test 'detectable' or 'undetectable' before I started treatment?
  5. 5.Based on my risk group, how does this score change the intensity or type of treatment you are recommending?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (8)
  1. 1

    Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-making.

    Chen SY, Yang Y, Qi SN, et al.

    Leukemia 2021; (35(1)):130-142 doi:10.1038/s41375-020-0791-3.

    PMID: 32152465
  2. 2

    [Comparison of Different Staging Systems of Extranodal NK/T Cell Lymphoma and Prognosis Analysis].

    Shi FQ, Zhao M, Jia Y, Wang JB

    Zhongguo shi yan xue ye xue za zhi 2026; (34(1)):79-85 doi:10.19746/j.cnki.issn.1009-2137.2026.01.011.

    PMID: 41846340
  3. 3

    A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

    Kim SJ, Yoon DH, Jaccard A, et al.

    The Lancet. Oncology 2016; (17(3)):389-400 doi:10.1016/S1470-2045(15)00533-1.

    PMID: 26873565
  4. 4

    Clinical Manifestations, Prognostic Factors, and Outcomes of Extranodal Natural Killer T-Cell Lymphoma: A Single-Center Experience in Thailand.

    Kaewboot W, Norasetthada L, Tantiworawit A, et al.

    Hematology reports 2024; (16(4)):769-780 doi:10.3390/hematolrep16040073.

    PMID: 39728003
  5. 5

    Evaluation of different staging systems and prognostic analysis of nasal-type extranodal NK/T-cell lymphoma based on consistent LVDP chemotherapy regimen.

    Wu W, Ren K, Li N, et al.

    Translational oncology 2022; (21()):101437 doi:10.1016/j.tranon.2022.101437.

    PMID: 35489119
  6. 6

    Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

    Fei Q, Tian XK, Wu J, et al.

    OncoTargets and therapy 2018; (11()):997-1004 doi:10.2147/OTT.S153942.

    PMID: 29520150
  7. 7

    The role of 18F-FDG PET/CT in diagnosing cardiac infiltration and therapeutic evaluation in extranodal nasal-type NK/T-cell lymphoma: a case report.

    Liao T, Li L, Fu G, et al.

    Frontiers in oncology 2025; (15()):1548785 doi:10.3389/fonc.2025.1548785.

    PMID: 40123904
  8. 8

    Recent advances in the diagnosis and treatment of natural killer/T-cell lymphomas.

    Tse E, Au-Yeung R, Kwong YL

    Expert review of hematology 2019; (12(11)):927-935 doi:10.1080/17474086.2019.1660640.

    PMID: 31487202

This page explains ENKTL staging and risk scores for educational purposes only. Always consult your oncologist to interpret your specific PINK-E score and treatment plan.

Get notified when new evidence is published on Extranodal nasal NK/T cell lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.